一种circRNA标志物及其在制备心梗后心肌纤维化诊断试剂盒及治疗药物中的应用
By using reverse transcription quantitative PCR of the circ-CELF1 marker and methods to inhibit its expression, we have solved the diagnostic and treatment challenges of myocardial infarction-related diseases, achieved effective intervention and diagnosis of myocardial fibrosis, and have significant clinical application potential.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HARBIN MEDICAL UNIVERSITY
- Filing Date
- 2025-07-18
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack sensitive circRNA biomarkers for myocardial infarction-related diseases, making it difficult to effectively intervene in the development of myocardial fibrosis.
This study provides the circRNA biomarker circ-CELF1 and its applications, including reverse transcription quantitative PCR primers that specifically amplify the circ-CELF1 back splice junction, for the preparation of diagnostic kits for myocardial fibrosis after myocardial infarction, and the preparation of therapeutic drugs using nucleic acid fragments or recombinant vectors that inhibit circ-CELF1 expression or reduce its activity.
circ-CELF1 has been successfully identified as a novel biomarker for myocardial fibrosis. It can significantly reduce the expression of myocardial fibrosis markers, improve myocardial fibrosis, and provide an effective molecular target for myocardial fibrosis drugs, which has clinical diagnostic and therapeutic value.
Smart Images
Figure CN120758618B_ABST